nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—hematologic cancer	0.134	1	CbGaD
Fesoterodine—ABCB1—Lenalidomide—hematologic cancer	0.0288	0.0527	CbGbCtD
Fesoterodine—CYP2D6—Lomustine—hematologic cancer	0.0252	0.0462	CbGbCtD
Fesoterodine—CYP2D6—Idarubicin—hematologic cancer	0.0225	0.0412	CbGbCtD
Fesoterodine—CYP2D6—Hydroxyurea—hematologic cancer	0.0191	0.035	CbGbCtD
Fesoterodine—CYP3A4—Bexarotene—hematologic cancer	0.0172	0.0316	CbGbCtD
Fesoterodine—ABCB1—Daunorubicin—hematologic cancer	0.0169	0.0309	CbGbCtD
Fesoterodine—CYP2D6—Bortezomib—hematologic cancer	0.0166	0.0305	CbGbCtD
Fesoterodine—ABCB1—Alitretinoin—hematologic cancer	0.0165	0.0303	CbGbCtD
Fesoterodine—CYP3A4—Busulfan—hematologic cancer	0.016	0.0294	CbGbCtD
Fesoterodine—CYP3A4—Lomustine—hematologic cancer	0.016	0.0294	CbGbCtD
Fesoterodine—CYP3A4—Thiotepa—hematologic cancer	0.0143	0.0262	CbGbCtD
Fesoterodine—ABCB1—Imatinib—hematologic cancer	0.0129	0.0237	CbGbCtD
Fesoterodine—CYP2D6—Imatinib—hematologic cancer	0.0122	0.0223	CbGbCtD
Fesoterodine—ABCB1—Nilotinib—hematologic cancer	0.0117	0.0215	CbGbCtD
Fesoterodine—ABCB1—Vinorelbine—hematologic cancer	0.0116	0.0213	CbGbCtD
Fesoterodine—CYP3A4—Methoxsalen—hematologic cancer	0.0111	0.0204	CbGbCtD
Fesoterodine—CYP2D6—Nilotinib—hematologic cancer	0.0111	0.0203	CbGbCtD
Fesoterodine—CYP2D6—Vinorelbine—hematologic cancer	0.011	0.0201	CbGbCtD
Fesoterodine—CYP3A4—Bortezomib—hematologic cancer	0.0106	0.0194	CbGbCtD
Fesoterodine—ABCB1—Dasatinib—hematologic cancer	0.0104	0.019	CbGbCtD
Fesoterodine—ABCB1—Mitoxantrone—hematologic cancer	0.0102	0.0188	CbGbCtD
Fesoterodine—CYP3A4—Daunorubicin—hematologic cancer	0.0101	0.0185	CbGbCtD
Fesoterodine—ABCB1—Betamethasone—hematologic cancer	0.00913	0.0167	CbGbCtD
Fesoterodine—ABCB1—Gemcitabine—hematologic cancer	0.00905	0.0166	CbGbCtD
Fesoterodine—ABCB1—Prednisolone—hematologic cancer	0.00901	0.0165	CbGbCtD
Fesoterodine—CYP3A4—Cytarabine—hematologic cancer	0.00891	0.0163	CbGbCtD
Fesoterodine—CYP3A4—Teniposide—hematologic cancer	0.00878	0.0161	CbGbCtD
Fesoterodine—ABCB1—Prednisone—hematologic cancer	0.00851	0.0156	CbGbCtD
Fesoterodine—CYP3A4—Ifosfamide—hematologic cancer	0.0081	0.0149	CbGbCtD
Fesoterodine—ABCB1—Irinotecan—hematologic cancer	0.00807	0.0148	CbGbCtD
Fesoterodine—CYP3A4—Imatinib—hematologic cancer	0.00774	0.0142	CbGbCtD
Fesoterodine—CYP3A4—Ruxolitinib—hematologic cancer	0.00729	0.0134	CbGbCtD
Fesoterodine—ABCB1—Vinblastine—hematologic cancer	0.00717	0.0131	CbGbCtD
Fesoterodine—ABCB1—Vincristine—hematologic cancer	0.00705	0.0129	CbGbCtD
Fesoterodine—CYP3A4—Nilotinib—hematologic cancer	0.00703	0.0129	CbGbCtD
Fesoterodine—CYP3A4—Vinorelbine—hematologic cancer	0.00697	0.0128	CbGbCtD
Fesoterodine—CYP2D6—Vinblastine—hematologic cancer	0.00676	0.0124	CbGbCtD
Fesoterodine—ABCB1—Cisplatin—hematologic cancer	0.00658	0.0121	CbGbCtD
Fesoterodine—ABCB1—Etoposide—hematologic cancer	0.00646	0.0118	CbGbCtD
Fesoterodine—CYP3A4—Triamcinolone—hematologic cancer	0.00638	0.0117	CbGbCtD
Fesoterodine—CYP3A4—Dasatinib—hematologic cancer	0.00622	0.0114	CbGbCtD
Fesoterodine—CYP3A4—Mitoxantrone—hematologic cancer	0.00614	0.0113	CbGbCtD
Fesoterodine—CYP3A4—Betamethasone—hematologic cancer	0.00547	0.01	CbGbCtD
Fesoterodine—CYP3A4—Prednisolone—hematologic cancer	0.0054	0.0099	CbGbCtD
Fesoterodine—ABCB1—Dexamethasone—hematologic cancer	0.00531	0.00974	CbGbCtD
Fesoterodine—CYP3A4—Prednisone—hematologic cancer	0.0051	0.00935	CbGbCtD
Fesoterodine—CYP2D6—Dexamethasone—hematologic cancer	0.00501	0.00918	CbGbCtD
Fesoterodine—CYP3A4—Irinotecan—hematologic cancer	0.00483	0.00886	CbGbCtD
Fesoterodine—ABCB1—Doxorubicin—hematologic cancer	0.00441	0.00808	CbGbCtD
Fesoterodine—CYP3A4—Vinblastine—hematologic cancer	0.0043	0.00788	CbGbCtD
Fesoterodine—ABCB1—Methotrexate—hematologic cancer	0.00427	0.00783	CbGbCtD
Fesoterodine—CYP3A4—Vincristine—hematologic cancer	0.00423	0.00775	CbGbCtD
Fesoterodine—CYP2D6—Doxorubicin—hematologic cancer	0.00415	0.00761	CbGbCtD
Fesoterodine—CYP3A4—Etoposide—hematologic cancer	0.00387	0.0071	CbGbCtD
Fesoterodine—CYP3A4—Dexamethasone—hematologic cancer	0.00318	0.00584	CbGbCtD
Fesoterodine—CYP3A4—Doxorubicin—hematologic cancer	0.00264	0.00484	CbGbCtD
Fesoterodine—Disopyramide—SLC22A1—hematologic cancer	0.000483	1	CrCbGaD
Fesoterodine—Gastrointestinal pain—Etoposide—hematologic cancer	6.78e-05	0.000277	CcSEcCtD
Fesoterodine—Infection—Betamethasone—hematologic cancer	6.78e-05	0.000277	CcSEcCtD
Fesoterodine—Infection—Dexamethasone—hematologic cancer	6.78e-05	0.000277	CcSEcCtD
Fesoterodine—Dizziness—Vincristine—hematologic cancer	6.77e-05	0.000276	CcSEcCtD
Fesoterodine—Rash—Carmustine—hematologic cancer	6.76e-05	0.000276	CcSEcCtD
Fesoterodine—Dermatitis—Carmustine—hematologic cancer	6.75e-05	0.000276	CcSEcCtD
Fesoterodine—Infestation NOS—Doxorubicin—hematologic cancer	6.74e-05	0.000275	CcSEcCtD
Fesoterodine—Infestation—Doxorubicin—hematologic cancer	6.74e-05	0.000275	CcSEcCtD
Fesoterodine—Feeling abnormal—Prednisolone—hematologic cancer	6.74e-05	0.000275	CcSEcCtD
Fesoterodine—Headache—Carmustine—hematologic cancer	6.71e-05	0.000274	CcSEcCtD
Fesoterodine—Rash—Alitretinoin—hematologic cancer	6.7e-05	0.000273	CcSEcCtD
Fesoterodine—Nervous system disorder—Betamethasone—hematologic cancer	6.69e-05	0.000273	CcSEcCtD
Fesoterodine—Nervous system disorder—Dexamethasone—hematologic cancer	6.69e-05	0.000273	CcSEcCtD
Fesoterodine—Dermatitis—Alitretinoin—hematologic cancer	6.69e-05	0.000273	CcSEcCtD
Fesoterodine—Hypersensitivity—Cisplatin—hematologic cancer	6.67e-05	0.000272	CcSEcCtD
Fesoterodine—Tachycardia—Betamethasone—hematologic cancer	6.66e-05	0.000272	CcSEcCtD
Fesoterodine—Tachycardia—Dexamethasone—hematologic cancer	6.66e-05	0.000272	CcSEcCtD
Fesoterodine—Headache—Alitretinoin—hematologic cancer	6.65e-05	0.000272	CcSEcCtD
Fesoterodine—Angioedema—Prednisone—hematologic cancer	6.65e-05	0.000272	CcSEcCtD
Fesoterodine—Diarrhoea—Gemcitabine—hematologic cancer	6.64e-05	0.000271	CcSEcCtD
Fesoterodine—Nausea—Thalidomide—hematologic cancer	6.63e-05	0.000271	CcSEcCtD
Fesoterodine—Dyspepsia—Triamcinolone—hematologic cancer	6.62e-05	0.00027	CcSEcCtD
Fesoterodine—Rash—Ifosfamide—hematologic cancer	6.62e-05	0.00027	CcSEcCtD
Fesoterodine—Dermatitis—Ifosfamide—hematologic cancer	6.61e-05	0.00027	CcSEcCtD
Fesoterodine—Dizziness—Irinotecan—hematologic cancer	6.59e-05	0.000269	CcSEcCtD
Fesoterodine—Urticaria—Etoposide—hematologic cancer	6.58e-05	0.000269	CcSEcCtD
Fesoterodine—Abdominal pain—Etoposide—hematologic cancer	6.55e-05	0.000268	CcSEcCtD
Fesoterodine—Urinary tract infection—Doxorubicin—hematologic cancer	6.55e-05	0.000268	CcSEcCtD
Fesoterodine—Vertigo—Prednisone—hematologic cancer	6.54e-05	0.000267	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—hematologic cancer	6.53e-05	0.000267	CcSEcCtD
Fesoterodine—Urticaria—Prednisolone—hematologic cancer	6.49e-05	0.000265	CcSEcCtD
Fesoterodine—Asthenia—Cisplatin—hematologic cancer	6.49e-05	0.000265	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—hematologic cancer	6.49e-05	0.000265	CcSEcCtD
Fesoterodine—Fatigue—Triamcinolone—hematologic cancer	6.48e-05	0.000265	CcSEcCtD
Fesoterodine—Urinary tract disorder—Epirubicin—hematologic cancer	6.46e-05	0.000264	CcSEcCtD
Fesoterodine—Rash—Vincristine—hematologic cancer	6.45e-05	0.000263	CcSEcCtD
Fesoterodine—Dermatitis—Vincristine—hematologic cancer	6.45e-05	0.000263	CcSEcCtD
Fesoterodine—Oedema peripheral—Epirubicin—hematologic cancer	6.44e-05	0.000263	CcSEcCtD
Fesoterodine—Urethral disorder—Epirubicin—hematologic cancer	6.41e-05	0.000262	CcSEcCtD
Fesoterodine—Headache—Vincristine—hematologic cancer	6.41e-05	0.000262	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Doxorubicin—hematologic cancer	6.37e-05	0.00026	CcSEcCtD
Fesoterodine—Nausea—Carmustine—hematologic cancer	6.37e-05	0.00026	CcSEcCtD
Fesoterodine—Nausea—Alitretinoin—hematologic cancer	6.31e-05	0.000258	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—hematologic cancer	6.3e-05	0.000257	CcSEcCtD
Fesoterodine—Rash—Mitoxantrone—hematologic cancer	6.28e-05	0.000257	CcSEcCtD
Fesoterodine—Rash—Irinotecan—hematologic cancer	6.28e-05	0.000257	CcSEcCtD
Fesoterodine—Dermatitis—Irinotecan—hematologic cancer	6.28e-05	0.000256	CcSEcCtD
Fesoterodine—Dermatitis—Mitoxantrone—hematologic cancer	6.28e-05	0.000256	CcSEcCtD
Fesoterodine—Headache—Mitoxantrone—hematologic cancer	6.24e-05	0.000255	CcSEcCtD
Fesoterodine—Headache—Irinotecan—hematologic cancer	6.24e-05	0.000255	CcSEcCtD
Fesoterodine—Nausea—Ifosfamide—hematologic cancer	6.23e-05	0.000255	CcSEcCtD
Fesoterodine—Feeling abnormal—Triamcinolone—hematologic cancer	6.2e-05	0.000253	CcSEcCtD
Fesoterodine—Diarrhoea—Cisplatin—hematologic cancer	6.19e-05	0.000253	CcSEcCtD
Fesoterodine—Insomnia—Dexamethasone—hematologic cancer	6.17e-05	0.000252	CcSEcCtD
Fesoterodine—Insomnia—Betamethasone—hematologic cancer	6.17e-05	0.000252	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	6.15e-05	0.000251	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—hematologic cancer	6.12e-05	0.00025	CcSEcCtD
Fesoterodine—Rash—Gemcitabine—hematologic cancer	6.12e-05	0.00025	CcSEcCtD
Fesoterodine—Dermatitis—Gemcitabine—hematologic cancer	6.11e-05	0.00025	CcSEcCtD
Fesoterodine—Eye disorder—Epirubicin—hematologic cancer	6.11e-05	0.00025	CcSEcCtD
Fesoterodine—Hypersensitivity—Etoposide—hematologic cancer	6.11e-05	0.000249	CcSEcCtD
Fesoterodine—Headache—Gemcitabine—hematologic cancer	6.08e-05	0.000248	CcSEcCtD
Fesoterodine—Nausea—Vincristine—hematologic cancer	6.08e-05	0.000248	CcSEcCtD
Fesoterodine—Cardiac disorder—Epirubicin—hematologic cancer	6.07e-05	0.000248	CcSEcCtD
Fesoterodine—Hypersensitivity—Prednisolone—hematologic cancer	6.02e-05	0.000246	CcSEcCtD
Fesoterodine—Dyspepsia—Dexamethasone—hematologic cancer	6e-05	0.000245	CcSEcCtD
Fesoterodine—Dyspepsia—Betamethasone—hematologic cancer	6e-05	0.000245	CcSEcCtD
Fesoterodine—Urinary tract disorder—Doxorubicin—hematologic cancer	5.98e-05	0.000244	CcSEcCtD
Fesoterodine—Urticaria—Triamcinolone—hematologic cancer	5.97e-05	0.000244	CcSEcCtD
Fesoterodine—Oedema peripheral—Doxorubicin—hematologic cancer	5.96e-05	0.000243	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—hematologic cancer	5.96e-05	0.000243	CcSEcCtD
Fesoterodine—Asthenia—Etoposide—hematologic cancer	5.95e-05	0.000243	CcSEcCtD
Fesoterodine—Urethral disorder—Doxorubicin—hematologic cancer	5.93e-05	0.000242	CcSEcCtD
Fesoterodine—Nausea—Irinotecan—hematologic cancer	5.92e-05	0.000242	CcSEcCtD
Fesoterodine—Nausea—Mitoxantrone—hematologic cancer	5.92e-05	0.000242	CcSEcCtD
Fesoterodine—Infection—Prednisone—hematologic cancer	5.9e-05	0.000241	CcSEcCtD
Fesoterodine—Mediastinal disorder—Epirubicin—hematologic cancer	5.89e-05	0.000241	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	5.89e-05	0.000241	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Betamethasone—hematologic cancer	5.89e-05	0.000241	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—hematologic cancer	5.88e-05	0.00024	CcSEcCtD
Fesoterodine—Fatigue—Betamethasone—hematologic cancer	5.88e-05	0.00024	CcSEcCtD
Fesoterodine—Fatigue—Dexamethasone—hematologic cancer	5.88e-05	0.00024	CcSEcCtD
Fesoterodine—Pruritus—Etoposide—hematologic cancer	5.86e-05	0.000239	CcSEcCtD
Fesoterodine—Nervous system disorder—Prednisone—hematologic cancer	5.83e-05	0.000238	CcSEcCtD
Fesoterodine—Tachycardia—Prednisone—hematologic cancer	5.8e-05	0.000237	CcSEcCtD
Fesoterodine—Skin disorder—Prednisone—hematologic cancer	5.77e-05	0.000236	CcSEcCtD
Fesoterodine—Nausea—Gemcitabine—hematologic cancer	5.77e-05	0.000235	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—hematologic cancer	5.73e-05	0.000234	CcSEcCtD
Fesoterodine—Mental disorder—Epirubicin—hematologic cancer	5.73e-05	0.000234	CcSEcCtD
Fesoterodine—Rash—Cisplatin—hematologic cancer	5.7e-05	0.000233	CcSEcCtD
Fesoterodine—Dermatitis—Cisplatin—hematologic cancer	5.7e-05	0.000233	CcSEcCtD
Fesoterodine—Diarrhoea—Etoposide—hematologic cancer	5.67e-05	0.000232	CcSEcCtD
Fesoterodine—Eye disorder—Doxorubicin—hematologic cancer	5.65e-05	0.000231	CcSEcCtD
Fesoterodine—Feeling abnormal—Betamethasone—hematologic cancer	5.62e-05	0.00023	CcSEcCtD
Fesoterodine—Feeling abnormal—Dexamethasone—hematologic cancer	5.62e-05	0.00023	CcSEcCtD
Fesoterodine—Cardiac disorder—Doxorubicin—hematologic cancer	5.62e-05	0.000229	CcSEcCtD
Fesoterodine—Flatulence—Epirubicin—hematologic cancer	5.61e-05	0.000229	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Dexamethasone—hematologic cancer	5.58e-05	0.000228	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Betamethasone—hematologic cancer	5.58e-05	0.000228	CcSEcCtD
Fesoterodine—Dysgeusia—Epirubicin—hematologic cancer	5.57e-05	0.000228	CcSEcCtD
Fesoterodine—Hypersensitivity—Triamcinolone—hematologic cancer	5.54e-05	0.000226	CcSEcCtD
Fesoterodine—Back pain—Epirubicin—hematologic cancer	5.51e-05	0.000225	CcSEcCtD
Fesoterodine—Dizziness—Etoposide—hematologic cancer	5.48e-05	0.000224	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—hematologic cancer	5.47e-05	0.000223	CcSEcCtD
Fesoterodine—Mediastinal disorder—Doxorubicin—hematologic cancer	5.45e-05	0.000223	CcSEcCtD
Fesoterodine—Urticaria—Dexamethasone—hematologic cancer	5.42e-05	0.000221	CcSEcCtD
Fesoterodine—Urticaria—Betamethasone—hematologic cancer	5.42e-05	0.000221	CcSEcCtD
Fesoterodine—Dizziness—Prednisolone—hematologic cancer	5.41e-05	0.000221	CcSEcCtD
Fesoterodine—Asthenia—Triamcinolone—hematologic cancer	5.39e-05	0.00022	CcSEcCtD
Fesoterodine—Abdominal pain—Betamethasone—hematologic cancer	5.39e-05	0.00022	CcSEcCtD
Fesoterodine—Abdominal pain—Dexamethasone—hematologic cancer	5.39e-05	0.00022	CcSEcCtD
Fesoterodine—Nausea—Cisplatin—hematologic cancer	5.37e-05	0.000219	CcSEcCtD
Fesoterodine—Insomnia—Prednisone—hematologic cancer	5.37e-05	0.000219	CcSEcCtD
Fesoterodine—Vision blurred—Epirubicin—hematologic cancer	5.37e-05	0.000219	CcSEcCtD
Fesoterodine—Pruritus—Triamcinolone—hematologic cancer	5.32e-05	0.000217	CcSEcCtD
Fesoterodine—Cough—Methotrexate—hematologic cancer	5.31e-05	0.000217	CcSEcCtD
Fesoterodine—Mental disorder—Doxorubicin—hematologic cancer	5.3e-05	0.000216	CcSEcCtD
Fesoterodine—Dyspepsia—Prednisone—hematologic cancer	5.23e-05	0.000214	CcSEcCtD
Fesoterodine—Rash—Etoposide—hematologic cancer	5.23e-05	0.000213	CcSEcCtD
Fesoterodine—Dermatitis—Etoposide—hematologic cancer	5.22e-05	0.000213	CcSEcCtD
Fesoterodine—Headache—Etoposide—hematologic cancer	5.19e-05	0.000212	CcSEcCtD
Fesoterodine—Flatulence—Doxorubicin—hematologic cancer	5.19e-05	0.000212	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—hematologic cancer	5.18e-05	0.000212	CcSEcCtD
Fesoterodine—Dysgeusia—Doxorubicin—hematologic cancer	5.16e-05	0.000211	CcSEcCtD
Fesoterodine—Rash—Prednisolone—hematologic cancer	5.15e-05	0.000211	CcSEcCtD
Fesoterodine—Dermatitis—Prednisolone—hematologic cancer	5.15e-05	0.00021	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	5.14e-05	0.00021	CcSEcCtD
Fesoterodine—Fatigue—Prednisone—hematologic cancer	5.12e-05	0.000209	CcSEcCtD
Fesoterodine—Headache—Prednisolone—hematologic cancer	5.12e-05	0.000209	CcSEcCtD
Fesoterodine—Vertigo—Epirubicin—hematologic cancer	5.11e-05	0.000209	CcSEcCtD
Fesoterodine—Back pain—Doxorubicin—hematologic cancer	5.1e-05	0.000208	CcSEcCtD
Fesoterodine—Constipation—Prednisone—hematologic cancer	5.08e-05	0.000207	CcSEcCtD
Fesoterodine—Palpitations—Epirubicin—hematologic cancer	5.03e-05	0.000205	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—hematologic cancer	5.01e-05	0.000204	CcSEcCtD
Fesoterodine—Dizziness—Triamcinolone—hematologic cancer	4.97e-05	0.000203	CcSEcCtD
Fesoterodine—Cough—Epirubicin—hematologic cancer	4.97e-05	0.000203	CcSEcCtD
Fesoterodine—Vision blurred—Doxorubicin—hematologic cancer	4.96e-05	0.000203	CcSEcCtD
Fesoterodine—Infection—Methotrexate—hematologic cancer	4.93e-05	0.000201	CcSEcCtD
Fesoterodine—Nausea—Etoposide—hematologic cancer	4.92e-05	0.000201	CcSEcCtD
Fesoterodine—Feeling abnormal—Prednisone—hematologic cancer	4.9e-05	0.0002	CcSEcCtD
Fesoterodine—Asthenia—Dexamethasone—hematologic cancer	4.89e-05	0.0002	CcSEcCtD
Fesoterodine—Asthenia—Betamethasone—hematologic cancer	4.89e-05	0.0002	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—hematologic cancer	4.87e-05	0.000199	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Prednisone—hematologic cancer	4.86e-05	0.000198	CcSEcCtD
Fesoterodine—Nausea—Prednisolone—hematologic cancer	4.86e-05	0.000198	CcSEcCtD
Fesoterodine—Chest pain—Epirubicin—hematologic cancer	4.85e-05	0.000198	CcSEcCtD
Fesoterodine—Pruritus—Dexamethasone—hematologic cancer	4.83e-05	0.000197	CcSEcCtD
Fesoterodine—Pruritus—Betamethasone—hematologic cancer	4.83e-05	0.000197	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—hematologic cancer	4.82e-05	0.000197	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	4.81e-05	0.000197	CcSEcCtD
Fesoterodine—Rash—Triamcinolone—hematologic cancer	4.74e-05	0.000194	CcSEcCtD
Fesoterodine—Dry mouth—Epirubicin—hematologic cancer	4.74e-05	0.000194	CcSEcCtD
Fesoterodine—Dermatitis—Triamcinolone—hematologic cancer	4.74e-05	0.000193	CcSEcCtD
Fesoterodine—Vertigo—Doxorubicin—hematologic cancer	4.73e-05	0.000193	CcSEcCtD
Fesoterodine—Urticaria—Prednisone—hematologic cancer	4.72e-05	0.000193	CcSEcCtD
Fesoterodine—Headache—Triamcinolone—hematologic cancer	4.71e-05	0.000192	CcSEcCtD
Fesoterodine—Abdominal pain—Prednisone—hematologic cancer	4.7e-05	0.000192	CcSEcCtD
Fesoterodine—Confusional state—Epirubicin—hematologic cancer	4.68e-05	0.000191	CcSEcCtD
Fesoterodine—Diarrhoea—Dexamethasone—hematologic cancer	4.67e-05	0.000191	CcSEcCtD
Fesoterodine—Diarrhoea—Betamethasone—hematologic cancer	4.67e-05	0.000191	CcSEcCtD
Fesoterodine—Palpitations—Doxorubicin—hematologic cancer	4.65e-05	0.00019	CcSEcCtD
Fesoterodine—Infection—Epirubicin—hematologic cancer	4.62e-05	0.000189	CcSEcCtD
Fesoterodine—Cough—Doxorubicin—hematologic cancer	4.6e-05	0.000188	CcSEcCtD
Fesoterodine—Nervous system disorder—Epirubicin—hematologic cancer	4.56e-05	0.000186	CcSEcCtD
Fesoterodine—Tachycardia—Epirubicin—hematologic cancer	4.53e-05	0.000185	CcSEcCtD
Fesoterodine—Skin disorder—Epirubicin—hematologic cancer	4.51e-05	0.000184	CcSEcCtD
Fesoterodine—Dizziness—Betamethasone—hematologic cancer	4.51e-05	0.000184	CcSEcCtD
Fesoterodine—Dizziness—Dexamethasone—hematologic cancer	4.51e-05	0.000184	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—hematologic cancer	4.49e-05	0.000183	CcSEcCtD
Fesoterodine—Chest pain—Doxorubicin—hematologic cancer	4.48e-05	0.000183	CcSEcCtD
Fesoterodine—Nausea—Triamcinolone—hematologic cancer	4.47e-05	0.000182	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	4.45e-05	0.000182	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—hematologic cancer	4.41e-05	0.00018	CcSEcCtD
Fesoterodine—Dry mouth—Doxorubicin—hematologic cancer	4.39e-05	0.000179	CcSEcCtD
Fesoterodine—Hypersensitivity—Prednisone—hematologic cancer	4.38e-05	0.000179	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—hematologic cancer	4.37e-05	0.000178	CcSEcCtD
Fesoterodine—Confusional state—Doxorubicin—hematologic cancer	4.33e-05	0.000177	CcSEcCtD
Fesoterodine—Rash—Dexamethasone—hematologic cancer	4.3e-05	0.000176	CcSEcCtD
Fesoterodine—Rash—Betamethasone—hematologic cancer	4.3e-05	0.000176	CcSEcCtD
Fesoterodine—Dermatitis—Dexamethasone—hematologic cancer	4.3e-05	0.000175	CcSEcCtD
Fesoterodine—Dermatitis—Betamethasone—hematologic cancer	4.3e-05	0.000175	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—hematologic cancer	4.29e-05	0.000175	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—hematologic cancer	4.28e-05	0.000175	CcSEcCtD
Fesoterodine—Headache—Betamethasone—hematologic cancer	4.27e-05	0.000175	CcSEcCtD
Fesoterodine—Headache—Dexamethasone—hematologic cancer	4.27e-05	0.000175	CcSEcCtD
Fesoterodine—Infection—Doxorubicin—hematologic cancer	4.27e-05	0.000174	CcSEcCtD
Fesoterodine—Asthenia—Prednisone—hematologic cancer	4.26e-05	0.000174	CcSEcCtD
Fesoterodine—Nervous system disorder—Doxorubicin—hematologic cancer	4.22e-05	0.000172	CcSEcCtD
Fesoterodine—Pruritus—Prednisone—hematologic cancer	4.2e-05	0.000172	CcSEcCtD
Fesoterodine—Insomnia—Epirubicin—hematologic cancer	4.2e-05	0.000172	CcSEcCtD
Fesoterodine—Tachycardia—Doxorubicin—hematologic cancer	4.2e-05	0.000171	CcSEcCtD
Fesoterodine—Skin disorder—Doxorubicin—hematologic cancer	4.18e-05	0.000171	CcSEcCtD
Fesoterodine—Somnolence—Epirubicin—hematologic cancer	4.13e-05	0.000169	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—hematologic cancer	4.09e-05	0.000167	CcSEcCtD
Fesoterodine—Dyspepsia—Epirubicin—hematologic cancer	4.09e-05	0.000167	CcSEcCtD
Fesoterodine—Diarrhoea—Prednisone—hematologic cancer	4.06e-05	0.000166	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—hematologic cancer	4.06e-05	0.000166	CcSEcCtD
Fesoterodine—Nausea—Dexamethasone—hematologic cancer	4.05e-05	0.000165	CcSEcCtD
Fesoterodine—Nausea—Betamethasone—hematologic cancer	4.05e-05	0.000165	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.01e-05	0.000164	CcSEcCtD
Fesoterodine—Fatigue—Epirubicin—hematologic cancer	4.01e-05	0.000164	CcSEcCtD
Fesoterodine—Constipation—Epirubicin—hematologic cancer	3.97e-05	0.000162	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—hematologic cancer	3.94e-05	0.000161	CcSEcCtD
Fesoterodine—Dizziness—Prednisone—hematologic cancer	3.93e-05	0.00016	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—hematologic cancer	3.92e-05	0.00016	CcSEcCtD
Fesoterodine—Insomnia—Doxorubicin—hematologic cancer	3.89e-05	0.000159	CcSEcCtD
Fesoterodine—Feeling abnormal—Epirubicin—hematologic cancer	3.83e-05	0.000156	CcSEcCtD
Fesoterodine—Somnolence—Doxorubicin—hematologic cancer	3.82e-05	0.000156	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Epirubicin—hematologic cancer	3.8e-05	0.000155	CcSEcCtD
Fesoterodine—Dyspepsia—Doxorubicin—hematologic cancer	3.78e-05	0.000155	CcSEcCtD
Fesoterodine—Rash—Prednisone—hematologic cancer	3.75e-05	0.000153	CcSEcCtD
Fesoterodine—Dermatitis—Prednisone—hematologic cancer	3.74e-05	0.000153	CcSEcCtD
Fesoterodine—Headache—Prednisone—hematologic cancer	3.72e-05	0.000152	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	3.71e-05	0.000152	CcSEcCtD
Fesoterodine—Fatigue—Doxorubicin—hematologic cancer	3.71e-05	0.000151	CcSEcCtD
Fesoterodine—Urticaria—Epirubicin—hematologic cancer	3.69e-05	0.000151	CcSEcCtD
Fesoterodine—Constipation—Doxorubicin—hematologic cancer	3.68e-05	0.00015	CcSEcCtD
Fesoterodine—Abdominal pain—Epirubicin—hematologic cancer	3.67e-05	0.00015	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—hematologic cancer	3.66e-05	0.000149	CcSEcCtD
Fesoterodine—Asthenia—Methotrexate—hematologic cancer	3.56e-05	0.000145	CcSEcCtD
Fesoterodine—Feeling abnormal—Doxorubicin—hematologic cancer	3.54e-05	0.000145	CcSEcCtD
Fesoterodine—Nausea—Prednisone—hematologic cancer	3.53e-05	0.000144	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Doxorubicin—hematologic cancer	3.52e-05	0.000144	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—hematologic cancer	3.51e-05	0.000143	CcSEcCtD
Fesoterodine—Hypersensitivity—Epirubicin—hematologic cancer	3.42e-05	0.00014	CcSEcCtD
Fesoterodine—Urticaria—Doxorubicin—hematologic cancer	3.42e-05	0.000139	CcSEcCtD
Fesoterodine—Abdominal pain—Doxorubicin—hematologic cancer	3.4e-05	0.000139	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—hematologic cancer	3.4e-05	0.000139	CcSEcCtD
Fesoterodine—Asthenia—Epirubicin—hematologic cancer	3.33e-05	0.000136	CcSEcCtD
Fesoterodine—Pruritus—Epirubicin—hematologic cancer	3.29e-05	0.000134	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—hematologic cancer	3.28e-05	0.000134	CcSEcCtD
Fesoterodine—Diarrhoea—Epirubicin—hematologic cancer	3.18e-05	0.00013	CcSEcCtD
Fesoterodine—Hypersensitivity—Doxorubicin—hematologic cancer	3.17e-05	0.000129	CcSEcCtD
Fesoterodine—Rash—Methotrexate—hematologic cancer	3.13e-05	0.000128	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—hematologic cancer	3.13e-05	0.000128	CcSEcCtD
Fesoterodine—Headache—Methotrexate—hematologic cancer	3.11e-05	0.000127	CcSEcCtD
Fesoterodine—Asthenia—Doxorubicin—hematologic cancer	3.08e-05	0.000126	CcSEcCtD
Fesoterodine—Dizziness—Epirubicin—hematologic cancer	3.07e-05	0.000125	CcSEcCtD
Fesoterodine—Pruritus—Doxorubicin—hematologic cancer	3.04e-05	0.000124	CcSEcCtD
Fesoterodine—Nausea—Methotrexate—hematologic cancer	2.95e-05	0.00012	CcSEcCtD
Fesoterodine—Diarrhoea—Doxorubicin—hematologic cancer	2.94e-05	0.00012	CcSEcCtD
Fesoterodine—Rash—Epirubicin—hematologic cancer	2.93e-05	0.00012	CcSEcCtD
Fesoterodine—Dermatitis—Epirubicin—hematologic cancer	2.93e-05	0.00012	CcSEcCtD
Fesoterodine—Headache—Epirubicin—hematologic cancer	2.91e-05	0.000119	CcSEcCtD
Fesoterodine—Dizziness—Doxorubicin—hematologic cancer	2.84e-05	0.000116	CcSEcCtD
Fesoterodine—Nausea—Epirubicin—hematologic cancer	2.76e-05	0.000113	CcSEcCtD
Fesoterodine—Rash—Doxorubicin—hematologic cancer	2.71e-05	0.000111	CcSEcCtD
Fesoterodine—Dermatitis—Doxorubicin—hematologic cancer	2.71e-05	0.000111	CcSEcCtD
Fesoterodine—Headache—Doxorubicin—hematologic cancer	2.69e-05	0.00011	CcSEcCtD
Fesoterodine—Nausea—Doxorubicin—hematologic cancer	2.55e-05	0.000104	CcSEcCtD
Fesoterodine—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	4.86e-06	6.47e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	4.83e-06	6.43e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1B—hematologic cancer	4.82e-06	6.42e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BAD—hematologic cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NFKBIA—hematologic cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—NCOR1—hematologic cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—GSTM1—hematologic cancer	4.81e-06	6.41e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CCND1—hematologic cancer	4.8e-06	6.4e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ENO2—hematologic cancer	4.8e-06	6.39e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—JUN—hematologic cancer	4.79e-06	6.38e-05	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—AKT1—hematologic cancer	4.77e-06	6.35e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NOTCH1—hematologic cancer	4.76e-06	6.35e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CD80—hematologic cancer	4.73e-06	6.3e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CASP3—hematologic cancer	4.72e-06	6.29e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	4.72e-06	6.29e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KIT—hematologic cancer	4.72e-06	6.29e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	4.72e-06	6.29e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL2—hematologic cancer	4.72e-06	6.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CD80—hematologic cancer	4.71e-06	6.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	4.71e-06	6.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KIT—hematologic cancer	4.71e-06	6.27e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	4.71e-06	6.27e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—IL6—hematologic cancer	4.69e-06	6.25e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3R1—hematologic cancer	4.67e-06	6.22e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CD80—hematologic cancer	4.67e-06	6.22e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ABCB1—hematologic cancer	4.67e-06	6.22e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	4.66e-06	6.21e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KIT—hematologic cancer	4.66e-06	6.21e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	4.66e-06	6.21e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTT1—hematologic cancer	4.65e-06	6.2e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	4.65e-06	6.19e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	4.64e-06	6.18e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PTEN—hematologic cancer	4.64e-06	6.17e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	4.62e-06	6.16e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CCND1—hematologic cancer	4.6e-06	6.13e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—JUN—hematologic cancer	4.59e-06	6.11e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	4.58e-06	6.1e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—SDC1—hematologic cancer	4.55e-06	6.06e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	4.53e-06	6.04e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.53e-06	6.04e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.53e-06	6.04e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	4.52e-06	6.02e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	4.52e-06	6.02e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	4.51e-06	6e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	4.49e-06	5.99e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CREB1—hematologic cancer	4.48e-06	5.97e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	4.46e-06	5.94e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	4.45e-06	5.93e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PTEN—hematologic cancer	4.44e-06	5.91e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	4.44e-06	5.91e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CREB1—hematologic cancer	4.44e-06	5.91e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	4.42e-06	5.89e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EP300—hematologic cancer	4.42e-06	5.89e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	4.4e-06	5.86e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	4.38e-06	5.84e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	4.38e-06	5.84e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	4.38e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	4.38e-06	5.83e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	4.37e-06	5.82e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	4.36e-06	5.81e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	4.34e-06	5.78e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	4.34e-06	5.78e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	4.33e-06	5.77e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	4.33e-06	5.76e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	4.32e-06	5.75e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CB—hematologic cancer	4.31e-06	5.74e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—SRC—hematologic cancer	4.3e-06	5.73e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MTHFR—hematologic cancer	4.25e-06	5.66e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EP300—hematologic cancer	4.23e-06	5.64e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	4.19e-06	5.58e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	4.18e-06	5.56e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	4.16e-06	5.55e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	4.15e-06	5.53e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—STAT3—hematologic cancer	4.15e-06	5.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	4.14e-06	5.51e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—NRAS—hematologic cancer	4.14e-06	5.51e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	4.12e-06	5.49e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—SRC—hematologic cancer	4.12e-06	5.48e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.11e-06	5.48e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	4.1e-06	5.46e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	4.1e-06	5.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	4.06e-06	5.41e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.06e-06	5.4e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	4.05e-06	5.39e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	4.01e-06	5.34e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	4.01e-06	5.34e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MTHFR—hematologic cancer	4e-06	5.33e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	3.97e-06	5.29e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—STAT3—hematologic cancer	3.97e-06	5.29e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	3.96e-06	5.28e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	3.96e-06	5.28e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—NRAS—hematologic cancer	3.96e-06	5.28e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	3.92e-06	5.22e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	3.92e-06	5.22e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	3.91e-06	5.2e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	3.87e-06	5.15e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CD44—hematologic cancer	3.87e-06	5.15e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NQO1—hematologic cancer	3.87e-06	5.15e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—MYC—hematologic cancer	3.85e-06	5.13e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	3.84e-06	5.12e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	3.81e-06	5.07e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	3.8e-06	5.06e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	3.79e-06	5.05e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	3.76e-06	5.01e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	3.73e-06	4.97e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PTEN—hematologic cancer	3.73e-06	4.96e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	3.72e-06	4.96e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	3.72e-06	4.95e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	3.71e-06	4.94e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—MYC—hematologic cancer	3.69e-06	4.91e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	3.68e-06	4.91e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	3.68e-06	4.9e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	3.67e-06	4.89e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CYCS—hematologic cancer	3.66e-06	4.87e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.63e-06	4.84e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	3.62e-06	4.82e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	3.62e-06	4.82e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	3.61e-06	4.8e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	3.61e-06	4.8e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CG—hematologic cancer	3.57e-06	4.76e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	3.57e-06	4.76e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	3.57e-06	4.76e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—KRAS—hematologic cancer	3.56e-06	4.74e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—EP300—hematologic cancer	3.55e-06	4.73e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	3.45e-06	4.6e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	3.44e-06	4.59e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	3.41e-06	4.54e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—KRAS—hematologic cancer	3.41e-06	4.54e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	3.39e-06	4.52e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	3.38e-06	4.51e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.36e-06	4.48e-05	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	3.36e-06	4.47e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	3.35e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	3.35e-06	4.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	3.33e-06	4.43e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL2—hematologic cancer	3.32e-06	4.42e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	3.32e-06	4.42e-05	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	3.31e-06	4.42e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL2—hematologic cancer	3.31e-06	4.41e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CREBBP—hematologic cancer	3.31e-06	4.41e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	3.31e-06	4.4e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	3.29e-06	4.39e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	3.28e-06	4.37e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL2—hematologic cancer	3.28e-06	4.37e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	3.27e-06	4.36e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	3.26e-06	4.35e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	3.24e-06	4.31e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—JUN—hematologic cancer	3.23e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	3.23e-06	4.3e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.22e-06	4.29e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—JUN—hematologic cancer	3.22e-06	4.29e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	3.2e-06	4.26e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—JUN—hematologic cancer	3.19e-06	4.25e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—TP53—hematologic cancer	3.16e-06	4.21e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CD—hematologic cancer	3.14e-06	4.18e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.13e-06	4.17e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	3.13e-06	4.17e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	3.13e-06	4.16e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	3.12e-06	4.16e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.12e-06	4.16e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	3.12e-06	4.15e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—ALB—hematologic cancer	3.1e-06	4.13e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	3.09e-06	4.12e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	3.09e-06	4.11e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	3.06e-06	4.07e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.05e-06	4.07e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	3.05e-06	4.06e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	3.05e-06	4.06e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	3.04e-06	4.05e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—TP53—hematologic cancer	3.03e-06	4.04e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	3.03e-06	4.03e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	3.02e-06	4.02e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	3.01e-06	4.01e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EP300—hematologic cancer	2.98e-06	3.97e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EP300—hematologic cancer	2.97e-06	3.96e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3R1—hematologic cancer	2.96e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—NCOR1—hematologic cancer	2.96e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—GSTM1—hematologic cancer	2.96e-06	3.95e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	2.96e-06	3.94e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EP300—hematologic cancer	2.94e-06	3.92e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—ALB—hematologic cancer	2.92e-06	3.89e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—SRC—hematologic cancer	2.9e-06	3.86e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	2.9e-06	3.86e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—IL6—hematologic cancer	2.9e-06	3.86e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—SRC—hematologic cancer	2.89e-06	3.85e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—SRC—hematologic cancer	2.86e-06	3.81e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	2.82e-06	3.76e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	2.81e-06	3.75e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	2.8e-06	3.72e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	2.79e-06	3.72e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	2.79e-06	3.71e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	2.79e-06	3.71e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	2.79e-06	3.71e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	2.78e-06	3.7e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—IL6—hematologic cancer	2.77e-06	3.69e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	2.76e-06	3.68e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	2.75e-06	3.67e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CB—hematologic cancer	2.74e-06	3.64e-05	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	2.67e-06	3.56e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	2.67e-06	3.56e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	2.66e-06	3.55e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	2.64e-06	3.51e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—PIK3CA—hematologic cancer	2.63e-06	3.5e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.62e-06	3.49e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—MYC—hematologic cancer	2.6e-06	3.46e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	2.59e-06	3.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—MYC—hematologic cancer	2.59e-06	3.45e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	2.58e-06	3.44e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.58e-06	3.43e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—MYC—hematologic cancer	2.56e-06	3.42e-05	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	2.56e-06	3.41e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	2.56e-06	3.41e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	2.4e-06	3.2e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	2.39e-06	3.19e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	2.37e-06	3.16e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PTEN—hematologic cancer	2.36e-06	3.15e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—EP300—hematologic cancer	2.25e-06	3e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.23e-06	2.97e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.2e-06	2.94e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.2e-06	2.93e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	2.2e-06	2.93e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	2.18e-06	2.9e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—AKT1—hematologic cancer	2.15e-06	2.86e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.13e-06	2.84e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.13e-06	2.83e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—EP300—hematologic cancer	2.12e-06	2.83e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—TP53—hematologic cancer	2.11e-06	2.8e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.04e-06	2.72e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.04e-06	2.72e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.03e-06	2.71e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	2.68e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—IL6—hematologic cancer	1.95e-06	2.6e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—IL6—hematologic cancer	1.95e-06	2.59e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.93e-06	2.58e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—IL6—hematologic cancer	1.93e-06	2.57e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—ALB—hematologic cancer	1.91e-06	2.54e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.83e-06	2.43e-05	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.8e-06	2.4e-05	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.8e-06	2.39e-05	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.78e-06	2.37e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.69e-06	2.25e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.67e-06	2.22e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.57e-06	2.09e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.46e-06	1.94e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—EP300—hematologic cancer	1.39e-06	1.85e-05	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—AKT1—hematologic cancer	1.36e-06	1.81e-05	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.28e-06	1.71e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.03e-06	1.37e-05	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—AKT1—hematologic cancer	8.39e-07	1.12e-05	CbGpPWpGaD
